FDA Grants Breakthrough Device Designation to pTau 217 Blood Test for Alzheimer Disease

News
Written By Emily Scholler
Emily Scholler
Previous

CEOi Launches Three Part Podcast Series, “A Breakthrough in Alzheimer’s Diagnostics: Integrating Blood Tests into Clinical Practice” in partnership with Pri-Med
Next

Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use